Literature DB >> 11430850

Mood disorders in children and adolescents: psychopharmacological treatment.

G J Emslie1, T L Mayes.   

Abstract

Mood disorders are the leading causes of morbidity and mortality in children and adolescence. As a result, many adolescents are treated with psychopharmacologic agents such as antidepressants and mood stabilizers. To date, research into the safety and efficacy of these medications has lagged behind clinical practice. Several controlled trials of antidepressants in this population have recently been completed or are ongoing, yet few controlled trials of mood stabilizers have been conducted. Although acute efficacy of antidepressants is being addressed, many questions remain about pharmacological treatment of early-onset mood disorders. This article will focus on unmet research needs for the psychopharmacologic treatment of child and adolescent mood disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430850     DOI: 10.1016/s0006-3223(01)01149-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

Review 1.  Continuation and maintenance therapy of early-onset major depressive disorder.

Authors:  Graham J Emslie; Taryn L Mayes; Maryse Ruberu
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats.

Authors:  Sergio D Iñiguez; Brandon L Warren; Carlos A Bolaños-Guzmán
Journal:  Biol Psychiatry       Date:  2010-02-20       Impact factor: 13.382

Review 3.  Psychopharmacologic treatment of pediatric major depressive disorder.

Authors:  Khrista Boylan; Soledad Romero; Boris Birmaher
Journal:  Psychopharmacology (Berl)       Date:  2006-08-08       Impact factor: 4.530

4.  Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats.

Authors:  Eric M Parise; Lyonna F Alcantara; Brandon L Warren; Katherine N Wright; Roey Hadad; Omar K Sial; Kyle G Kroeck; Sergio D Iñiguez; Carlos A Bolaños-Guzmán
Journal:  Biol Psychiatry       Date:  2013-06-19       Impact factor: 13.382

Review 5.  Child and adolescent depression: short-term treatment effectiveness and long-term opportunities.

Authors:  Neal D Ryan
Journal:  Int J Methods Psychiatr Res       Date:  2003       Impact factor: 4.035

Review 6.  Contemporary assessment and pharmacotherapy of Tourette syndrome.

Authors:  Lawrence Scahill; Gerald Erenberg; Cheston M Berlin; Cathy Budman; Barbara J Coffey; Joseph Jankovic; Louise Kiessling; Robert A King; Roger Kurlan; Anthony Lang; Jonathan Mink; Tanya Murphy; Samual Zinner; John Walkup
Journal:  NeuroRx       Date:  2006-04

7.  Passive versus active parental permission: implications for the ability of school-based depression screening to reach youth at risk.

Authors:  Maggie Chartier; Ann Vander Stoep; Elizabeth McCauley; Jerald R Herting; Melissa Tracy; James Lymp
Journal:  J Sch Health       Date:  2008-03       Impact factor: 2.118

Review 8.  Diagnosis and treatment of dysthymia in children and adolescents.

Authors:  Maria Nobile; Giulia M Cataldo; Cecilia Marino; Massimo Molteni
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management.

Authors:  Steven R Pliszka
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Temporal trends in antidepressant prescribing to children in UK primary care, 2000-2015.

Authors:  Jane Sarginson; Roger T Webb; S Jill Stocks; Aneez Esmail; Shruti Garg; Darren M Ashcroft
Journal:  J Affect Disord       Date:  2017-01-02       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.